Yvonne Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016. Prior to joining Alnylam, Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer. Dr. Greenstreet was also at GlaxoSmithKline (GSK) for 18 years as Senior Vice President and Chief of Strategy for Research and Development. Dr. Greenstreet previously served in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development, in which she led the creation of a new global unit which had responsibility for GSK's musculoskeletal, endocrine, gastrointestinal, ophthalmology and urological disease areas. Prior to this role, she was Chief Medical Officer for GSK Europe, with responsibility for development and medical affairs of GSK’s entire pipeline and product portfolio in the region. Dr. Greenstreet currently serves on the Boards of Indivior PLC and Advanced Accelerator Applications S.A., as well as on the Scientific Advisory Board of the Bill and Melinda Gates Foundation. Dr. Greenstreet trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France. Yvonne Greenstreet has served as Executive Vice President and Chief Operating Officer of Alnylam Pharmaceuticals, a leading RNAi therapeutics company, since September 2016. Prior to joining Alnylam, Dr. Greenstreet was Senior Vice President and Head of Medicines Development at Pfizer. Dr. Greenstreet was also at GlaxoSmithKline (GSK) for 18 years as Senior Vice President and Chief of Strategy for Research and Development. Dr. Greenstreet previously served in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development, in which she led the creation of a new global unit which had responsibility for GSK's musculoskeletal, endocrine, gastrointestinal, ophthalmology and urological disease areas. Prior to this role, she was Chief Medical Officer for GSK Europe, with responsibility for development and medical affairs of GSK’s entire pipeline and product portfolio in the region. Dr. Greenstreet currently serves on the Boards of Indivior PLC and Advanced Accelerator Applications S.A., as well as on the Scientific Advisory Board of the Bill and Melinda Gates Foundation. Dr. Greenstreet trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France.

Oncology